Gonococcal Urethritis

Organism

N. gonorrhoeae. Gram-negative diplococcus, “KIDNEY BEAN”/coffee-bean shape (flattened adjacent surfaces). Hallmark: INTRACELLULAR within neutrophils (male urethral discharge). Oxidase+, fastidious, capnophilic (5-10% CO2). FRAGILE outside host (poor dry/room-temp survival) — essentially never fomite-transmitted, obligate STI/vertical pathogen.

Virulence Factors

Pili — attachment + ANTIGENIC/PHASE VARIATION (evades Ab, explains poor lasting immunity, common reinfection). Opa proteins — tighter adherence + epithelial invasion. LOS (lipooligosaccharide) — gonococcal LPS equivalent, shorter, no O-antigen repeats. Triggers inflammatory response → purulent discharge. IgA protease — cleaves mucosal secretory IgA, blunts mucosal defense.

Clinical Manifestations

Men: acute urethritis, copious PURULENT discharge + dysuria, SHORT incubation (2-5d). Usually SYMPTOMATIC → recognized/treated promptly → limits male asymptomatic reservoir.

Women: cervicitis primary site, FREQUENTLY ASYMPTOMATIC/mild (mucopurulent discharge, ±intermenstrual bleeding). Asymptomatic tendency = KEY epidemiological fact → silent persistence/transmission. PID: ascending untreated infection → endometrium+tubes → infertility, ectopic pregnancy, chronic pelvic pain. Can be FIRST recognized sign of otherwise-silent infection.

DGI (Disseminated Gonococcal Infection): bloodstream entry from mucosal site. TRIAD: migratory polyarthritis + tenosynovitis + sparse pustular/vesiculopustular rash (extremities). More common in: women (unrecognized cervical infection before dissemination), terminal complement deficiency (C5-C9, see Complement topic — needed to control gonococcal bacteremia).

Other sites: Gonococcal conjunctivitis (adult=autoinoculation; neonate=OPHTHALMIA NEONATORUM, vaginal delivery through infected cervix, potentially blinding → universal neonatal ocular prophylaxis standard). Pharyngeal/rectal gonorrhea (oral/anal contact, often asymptomatic, transmission/resistance reservoir).

Laboratory Diagnosis

Gram stain: symptomatic MALE — Gram-negative INTRACELLULAR diplococci in neutrophils = presumptively diagnostic alone (high sens/spec). WOMEN (endocervical) — MUCH LOWER sensitivity, not relied on same way.

Culture: selective media (Thayer-Martin, antibiotic-suppressed competing flora, CO2-enriched chocolate agar needed). Value: ONLY method allowing AST — critical given ongoing resistance drift.

NAAT: NOW METHOD OF CHOICE, superior sensitivity vs culture. Urine or self-collected vaginal swab (no pelvic exam needed for testing). Typically COMBINED N. gonorrhoeae/C. trachomatis panel (frequent co-infection).

Treatment

Historical resistance pattern: defeated sulfonamides→penicillin→tetracycline→fluoroquinolones sequentially as 1st-line. CEFTRIAXONE (single IM dose) = current standard 1st-line WORLDWIDE. EMPIRICAL CHLAMYDIA TREATMENT ADDED even without confirmed co-infection (frequent co-occurrence + serious untreated chlamydial consequences) — presumptive dual Rx standard, not wait-for-confirmation. Emerging cephalosporin resistance = ACTIVELY MONITORED globally — ceftriaxone = last reliable single-agent option, genuine concern re: untreatable disease if resistance spreads.

Prevention

Condoms, partner notification+treatment (reinfection from untreated partner common). Ophthalmia neonatorum: UNIVERSAL neonatal ocular prophylaxis at birth (regardless of maternal screening — screening gaps common enough that universal beats selective).

The Organism

Neisseria gonorrhoeae (gonococcus) is a Gram-negative diplococcus, characteristically arranged in pairs with adjacent flattened surfaces giving a “kidney bean” or coffee-bean appearance — a genuinely distinctive morphology worth fixing precisely, since it directly aids rapid presumptive diagnosis on Gram stain, especially the hallmark finding of organisms visible intracellularly within neutrophils in a symptomatic male urethral discharge specimen. It is oxidase-positive and a fastidious, capnophilic organism (needs enriched media and 5–10% CO₂), genuinely fragile outside the host — surviving poorly on dry surfaces or at room temperature, which is why it is essentially never transmitted by casual/fomite contact and remains an obligate sexually/vertically transmitted pathogen.

Virulence Factors

Gonococcal pathogenicity centres on several surface structures, each with a specific functional role: pili mediate initial attachment to mucosal epithelium and, through antigenic and phase variation (the organism can switch pilin expression on/off and vary its structure), evade a developing antibody response — a mechanism that also explains why natural infection confers little to no lasting protective immunity, making repeat gonococcal infection genuinely common. Opa proteins (opacity-associated outer membrane proteins) mediate tighter adherence and invasion into host epithelial cells. Lipooligosaccharide (LOS) — the gonococcal equivalent of LPS, though structurally shorter and lacking the O-antigen repeat units typical of most Gram-negative LPS — triggers the inflammatory response responsible for the purulent discharge that characterizes symptomatic disease. An IgA protease cleaves and inactivates mucosal secretory IgA, blunting the mucosal antibody defence specifically.

Clinical Manifestations

In men: acute urethritis with copious, purulent urethral discharge and dysuria, typically after a short incubation (2–5 days) — symptomatic enough in most men that the infection is usually recognized and treated promptly, which paradoxically limits how often men serve as an asymptomatic reservoir compared with women.

In women: cervicitis is the primary site, but is frequently asymptomatic or only mildly symptomatic (mucopurulent cervical discharge, sometimes intermenstrual bleeding) — this asymptomatic tendency in women is a genuinely important epidemiological fact, since it means untreated infection can persist and transmit silently, and is also the reason pelvic inflammatory disease (PID) is such a significant complication: ascending untreated infection into the endometrium and fallopian tubes causes PID, which itself risks infertility, ectopic pregnancy, and chronic pelvic pain — consequences that can be the first recognized sign of an infection that produced no earlier symptoms at all.

Disseminated gonococcal infection (DGI) occurs when the organism enters the bloodstream from a mucosal site, producing a distinctive triad — migratory polyarthritis, tenosynovitis, and a sparse pustular/vesiculopustular skin rash on the extremities — occurring more often in women (reflecting how often the underlying cervical infection went unrecognized and untreated before disseminating) and in patients with underlying terminal complement pathway deficiency (C5-C9, see Complement System), since these components are specifically needed to control gonococcal bacteraemia.

Other sites: gonococcal conjunctivitis (in adults, from autoinoculation; in neonates, ophthalmia neonatorum, acquired during vaginal delivery through an infected maternal cervix — a genuinely serious, potentially blinding infection, which is why prophylactic ocular antibiotic/silver-nitrate application to every newborn remains standard practice in many settings) and pharyngeal/rectal gonorrhoea (from oral/anal sexual contact, frequently asymptomatic, and a real reservoir for ongoing transmission and antimicrobial resistance selection given how often these sites go untested).

Laboratory Diagnosis

Gram stain: in a symptomatic male with urethral discharge, Gram-negative intracellular diplococci within neutrophils is highly sensitive and specific enough to be considered presumptively diagnostic on its own — a genuinely useful, immediate bedside/lab test. Gram stain sensitivity in women (endocervical specimens) is considerably lower, so it is not relied upon the same way for female diagnosis.

Culture on selective media (Thayer-Martin or similar, incorporating antibiotics to suppress competing flora, plus the CO₂-enriched, chocolate-agar-based growth requirements of this fastidious organism) remains valuable specifically because it is the only method that also permits antimicrobial susceptibility testing — an increasingly critical need given gonococcus’s well-documented, ongoing drift toward antimicrobial resistance (see Treatment below).

Nucleic acid amplification tests (NAAT) are now the diagnostic method of choice for most routine testing given superior sensitivity over culture, applicable to urine or self-collected vaginal swabs (avoiding the need for a pelvic exam purely for testing purposes) and typically run as a combined N. gonorrhoeae/Chlamydia trachomatis panel, since the two infections co-occur often enough that testing for one without the other is poor practice.

Treatment

Gonococcus’s rapid, historically demonstrated capacity to develop antimicrobial resistance (having successively defeated sulfonamides, penicillin, tetracycline, and fluoroquinolones as first-line therapy over the decades) is the central fact shaping current treatment guidance: ceftriaxone (a single IM dose) is now the standard first-line therapy essentially worldwide, and — reflecting the same “always assume co-infection” logic behind combined NAAT testing — empirical treatment for chlamydia is added even without confirmed co-infection, since the two infections are found together often enough, and untreated chlamydial co-infection has its own serious consequences (see Non-gonococcal Urethritis), that presumptive dual treatment is standard practice rather than waiting for a separate confirmatory result. Emerging cephalosporin resistance is being actively monitored globally, since ceftriaxone is currently the last remaining reliably effective single-agent option, and a genuine concern exists about the disease becoming effectively untreatable with any oral agent should resistance continue to spread.

Prevention

Condom use, partner notification and treatment (essential given how often reinfection occurs from an untreated partner), and — specifically for ophthalmia neonatorum — universal neonatal ocular prophylaxis at birth regardless of maternal screening status, since screening gaps and unrecognized maternal infection remain common enough that universal prophylaxis outperforms selective, risk-based prophylaxis.